1. Home
  2. LEGN vs FLR Comparison

LEGN vs FLR Comparison

Compare LEGN & FLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEGN
  • FLR
  • Stock Information
  • Founded
  • LEGN 2014
  • FLR 1912
  • Country
  • LEGN United States
  • FLR United States
  • Employees
  • LEGN N/A
  • FLR N/A
  • Industry
  • LEGN Biotechnology: Pharmaceutical Preparations
  • FLR Military/Government/Technical
  • Sector
  • LEGN Health Care
  • FLR Industrials
  • Exchange
  • LEGN Nasdaq
  • FLR Nasdaq
  • Market Cap
  • LEGN 7.0B
  • FLR 6.4B
  • IPO Year
  • LEGN 2020
  • FLR N/A
  • Fundamental
  • Price
  • LEGN $31.78
  • FLR $35.85
  • Analyst Decision
  • LEGN Strong Buy
  • FLR Strong Buy
  • Analyst Count
  • LEGN 13
  • FLR 7
  • Target Price
  • LEGN $79.42
  • FLR $45.71
  • AVG Volume (30 Days)
  • LEGN 1.5M
  • FLR 2.6M
  • Earning Date
  • LEGN 05-13-2025
  • FLR 05-02-2025
  • Dividend Yield
  • LEGN N/A
  • FLR N/A
  • EPS Growth
  • LEGN N/A
  • FLR 563.49
  • EPS
  • LEGN N/A
  • FLR 10.64
  • Revenue
  • LEGN $627,241,000.00
  • FLR $16,563,000,000.00
  • Revenue This Year
  • LEGN $65.96
  • FLR $13.24
  • Revenue Next Year
  • LEGN $52.55
  • FLR $5.16
  • P/E Ratio
  • LEGN N/A
  • FLR $3.36
  • Revenue Growth
  • LEGN 119.97
  • FLR 7.16
  • 52 Week Low
  • LEGN $29.27
  • FLR $29.20
  • 52 Week High
  • LEGN $60.87
  • FLR $60.10
  • Technical
  • Relative Strength Index (RSI)
  • LEGN 41.49
  • FLR 53.56
  • Support Level
  • LEGN $30.25
  • FLR $34.28
  • Resistance Level
  • LEGN $35.81
  • FLR $36.12
  • Average True Range (ATR)
  • LEGN 1.45
  • FLR 1.19
  • MACD
  • LEGN -0.18
  • FLR 0.25
  • Stochastic Oscillator
  • LEGN 27.58
  • FLR 57.50

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

About FLR Fluor Corporation

Fluor is one of the largest global providers of engineering, procurement, construction, fabrication, operations, and maintenance services. The firm serves a wide range of end markets including oil and gas, chemicals, mining, metals, and transportation. The company's business is organized into three core segments: urban solutions, mission solutions, and energy solutions. Fluor generated $16.3 billion in revenue in 2024.

Share on Social Networks: